[go: up one dir, main page]

LU91437I9 - - Google Patents

Info

Publication number
LU91437I9
LU91437I9 LU91437C LU91437C LU91437I9 LU 91437 I9 LU91437 I9 LU 91437I9 LU 91437 C LU91437 C LU 91437C LU 91437 C LU91437 C LU 91437C LU 91437 I9 LU91437 I9 LU 91437I9
Authority
LU
Luxembourg
Application number
LU91437C
Other versions
LU91437I2 (fr
Inventor
Uwe Ries
Norbert Hauel
Henning Priepke
Wolfgang Wienen
Jean Marie Stassen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26034058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91437(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19706229A external-priority patent/DE19706229A1/de
Priority claimed from DE1997151939 external-priority patent/DE19751939A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of LU91437I2 publication Critical patent/LU91437I2/fr
Publication of LU91437I9 publication Critical patent/LU91437I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/74—Sulfur atoms substituted by carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU91437C 1997-02-18 2008-05-14 "dabigatran-etexilate et ses sels- particulièrement dabigatran-etexilate-mésilate (PRADAXA)" LU91437I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19706229A DE19706229A1 (de) 1997-02-18 1997-02-18 Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
DE1997151939 DE19751939A1 (de) 1997-11-24 1997-11-24 Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP1998/000865 WO1998037075A1 (fr) 1997-02-18 1998-02-16 Heterocycles bicycliques disubstitues, production et utilisation comme medicaments

Publications (2)

Publication Number Publication Date
LU91437I2 LU91437I2 (fr) 2008-07-14
LU91437I9 true LU91437I9 (fr) 2019-01-02

Family

ID=26034058

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91437C LU91437I2 (fr) 1997-02-18 2008-05-14 "dabigatran-etexilate et ses sels- particulièrement dabigatran-etexilate-mésilate (PRADAXA)"

Country Status (38)

Country Link
EP (1) EP0966454B1 (fr)
JP (1) JP3343359B2 (fr)
KR (1) KR100619458B1 (fr)
CN (1) CN1088702C (fr)
AR (1) AR010896A1 (fr)
AT (1) ATE239712T1 (fr)
AU (1) AU742593C (fr)
BG (1) BG64558B1 (fr)
BR (1) BR9807843B1 (fr)
CA (1) CA2277949C (fr)
CO (1) CO4920237A1 (fr)
CZ (1) CZ297768B6 (fr)
DE (2) DE122008000020I1 (fr)
DK (1) DK0966454T3 (fr)
EA (1) EA003697B1 (fr)
EE (1) EE04716B1 (fr)
EG (1) EG24144A (fr)
ES (1) ES2199426T4 (fr)
FR (1) FR08C0025I2 (fr)
HR (1) HRP980082B1 (fr)
HU (1) HU223754B1 (fr)
IL (1) IL130812A (fr)
LT (1) LTC0966454I2 (fr)
LU (1) LU91437I2 (fr)
MY (1) MY129408A (fr)
NL (1) NL300349I2 (fr)
NO (3) NO313879B1 (fr)
NZ (1) NZ337323A (fr)
PE (1) PE121699A1 (fr)
PL (1) PL195551B1 (fr)
PT (1) PT966454E (fr)
RS (1) RS49686B (fr)
SA (1) SA98190047B1 (fr)
SI (1) SI0966454T1 (fr)
SK (1) SK285432B6 (fr)
TR (1) TR199902017T2 (fr)
TW (1) TW588047B (fr)
WO (1) WO1998037075A1 (fr)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026933A1 (fr) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. Derives d'amidinoaryle substitue et leur utilisation comme anticoagulants
JP2002502844A (ja) * 1998-02-03 2002-01-29 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用
US6114532A (en) * 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
ATE223408T1 (de) * 1998-02-09 2002-09-15 Dimensional Pharm Inc Heteroaryl-amidinen,-methylamidinen und - guanidinen als protease inhibitoren, insbesondere als urokinase inhibitoren
TWI248435B (en) * 1998-07-04 2006-02-01 Boehringer Ingelheim Pharma Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
US6248770B1 (en) 1998-07-09 2001-06-19 Boehringer Ingelheim Pharma Kg Benzimidazoles having antithrombotic activity
EP1150979A1 (fr) * 1999-02-09 2001-11-07 3-Dimensional Pharmaceuticals, Inc. Amidines, methylamidines et guanidines, heteroaryles, en tant qu'inhibiteurs de proteases
DE19907813A1 (de) * 1999-02-24 2000-08-31 Boehringer Ingelheim Pharma Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
US6512000B1 (en) 1999-08-20 2003-01-28 Boehringer Ingelheim Pharma Kg Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity
DE19939463A1 (de) * 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19945810A1 (de) * 1999-09-24 2001-03-29 Boehringer Ingelheim Pharma Substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6413990B1 (en) 1999-09-24 2002-07-02 Boehringer Ingelheim Pharma Kg Arylsulphonamide-substituted benzimidazoles having tryptase-inhibiting activity
DE19945787A1 (de) 1999-09-24 2001-03-29 Boehringer Ingelheim Pharma Arylsulfonamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU7288900A (en) * 1999-09-24 2001-04-30 Boehringer Ingelheim Pharma Kg Aryl sulfonamide-substituted benzimidazol derivatives thereof as tryptase inhibitors
US6407130B1 (en) 1999-11-10 2002-06-18 Boehringer Ingelheim Pharma Kg Carboxamide-substituted benzimidazoles having tryptase-inhibiting activity
US6451832B2 (en) 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CN100402499C (zh) 2001-04-19 2008-07-16 卫材R&D管理有限公司 2-亚氨基吡咯烷衍生物
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
PT1870100E (pt) 2002-03-07 2012-04-17 Boehringer Ingelheim Int Metanossulfonato de 3-[(2-{[4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10235639A1 (de) 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1546089A2 (fr) 2002-08-09 2005-06-29 TransTech Pharma Inc. Composes aryle et heteroaryle et procedes de modulation de la coagulation
PE20040804A1 (es) * 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
US7429597B2 (en) 2002-12-23 2008-09-30 Boehringer Ingelheim Pharma Gmbh & Co., Kg Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
DE10260730A1 (de) * 2002-12-23 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte stickstoffhaltige Heterobicyclen, deren Herstellung und deren Verwendung als Arzneimittel
EP1602646A4 (fr) 2003-02-19 2010-07-28 Eisai R&D Man Co Ltd Procedes de production de derive de benzamidine cyclique
DE10310278A1 (de) * 2003-03-10 2004-09-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue aromatische Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel
EP2062580A1 (fr) * 2003-04-24 2009-05-27 Boehringer Ingelheim International GmbH Utilisation de dipyridamole ou mopidamole pour le traitement et la prévention de maladies et de troubles thromboemboliques provoqués par la formation en excès de thrombine et/ou par l'expression élevée de récepteurs de la thrombine
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014532A1 (fr) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Composes aryle et heteroaryle, compositions et procedes associes
AU2004263508A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE10341043A1 (de) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
EP1609784A1 (fr) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Procédé pour la préparation de 4-(benzimidazolylméthylamino)-benzamidines
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) * 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
US7700620B2 (en) 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE102005061624A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
WO2007103996A1 (fr) 2006-03-09 2007-09-13 Bristol-Myers Squibb Company Inhibiteurs du facteur viia de type 2-(aryloxy)acétamide pouvant être employés en tant qu'anticoagulants
CN101500993A (zh) 2006-06-08 2009-08-05 百时美施贵宝公司 作为凝血因子Ⅶa抑制剂用作抗凝血药的2-氨基羰基苯基氨基-2-苯基乙酰胺
CA2657269A1 (fr) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh Nouvelles indications portant sur les inhibiteurs directs de la thrombine
WO2008009638A2 (fr) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh Nouvelles indications portant sur les inhibiteurs directs de la thrombine dans le domaine cardiovasculaire
EP2074112A1 (fr) * 2006-10-10 2009-07-01 Boehringer Ingelheim International GmbH Sels physiologiquement acceptables de l'ester éthylique de l'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino-méthyl)-phénylamino]-méthyl}-1-méthyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionique.
ES2546815T3 (es) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
EP1956018A1 (fr) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé de préparation d'un dérivé du benzimidazole
CN101663293B (zh) 2007-04-23 2013-07-31 塞诺菲-安万特股份有限公司 作为p2y12拮抗剂的喹啉-甲酰胺衍生物
EP2178849A1 (fr) 2007-07-31 2010-04-28 Mallinckrodt Inc. Agents photoactifs intégrés et leurs utilisations
EP2238128B1 (fr) 2007-12-26 2012-08-22 Sanofi Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
CZ305085B6 (cs) * 2008-03-14 2015-04-29 Zentiva, K.S. Způsob přípravy dabigatranu
CN102099012A (zh) 2008-07-14 2011-06-15 贝林格尔.英格海姆国际有限公司 制备含有达比加群的药物制剂的方法
WO2010020600A1 (fr) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Utilisation du dabigatran-étexilate pour le traitement de patients souffrant d’hypertension pulmonaire
CZ2008669A3 (cs) * 2008-10-24 2010-05-05 Zentiva, A. S. Zpusob prípravy dabigatranu a jeho meziprodukty
MX2011007301A (es) * 2009-02-02 2011-08-03 Boehringer Ingelheim Int Dabigatran liofilizado.
WO2010130757A1 (fr) 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh Nouvelle polytherapie destinee a traiter les maladies oncologiques et fibrotiques
NZ597359A (en) 2009-08-24 2014-01-31 Boehringer Ingelheim Int Emergency interventions of active charcoal with dabigatran etexilate overdosing
CN102050815B (zh) * 2009-11-06 2014-04-02 北京美倍他药物研究有限公司 作为前药的达比加群的酯衍生物
CN102050814B (zh) * 2009-11-06 2014-05-28 北京美倍他药物研究有限公司 达比加群的酯衍生物
US8399678B2 (en) 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate
TWI513466B (zh) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
HUP1000069A2 (en) 2010-02-02 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag New salts for the preparation of pharmaceutical composition
EP3786165A1 (fr) 2010-02-11 2021-03-03 Bristol-Myers Squibb Company Intermédiaires de synthèse utiles à la préparation de macrocycles utilisés en tant qu'inhibiteurs du facteur xia
DK2542224T3 (da) 2010-03-01 2014-10-20 Ratiopharm Gmbh Oral farmaceutisk sammensætning indeholdende dabigatranetexilat
CA2792273A1 (fr) 2010-03-08 2011-09-15 Ratiopharm Gmbh Composition pharmaceutique contenant du dabigatran etexilate
US20130177652A1 (en) 2010-07-01 2013-07-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
MX2013000295A (es) 2010-07-09 2013-05-28 Esteve Quimica Sa Procedimiento de preparacion de un inhibidor especifico de la trombina.
CN103025715A (zh) 2010-07-09 2013-04-03 埃斯特维化学股份有限公司 用于制备凝血酶特异性抑制剂的中间体和方法
WO2012027543A1 (fr) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Formes solides de dabigatran étexilate et de dabigatran étexilate mésylate et leurs méthodes de préparation
WO2012077136A2 (fr) 2010-12-06 2012-06-14 Msn Laboratories Limited Procédé de préparation de dérivés de benzimidazole et de leurs sels
JP5931752B2 (ja) 2011-02-01 2016-06-08 協和発酵キリン株式会社 縮環複素環誘導体
SG193552A1 (en) 2011-03-30 2013-11-29 Boehringer Ingelheim Int Anticoagulant antidotes
HUP1100244A2 (hu) 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Gyógyszeripari intermedierek és eljárás elõállításukra
CN102250099B (zh) * 2011-05-16 2013-10-16 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
CN102838588B (zh) * 2011-06-24 2014-03-19 中国药科大学 一类可用于口服的凝血酶抑制剂、其制法以及医药用途
PT2550966T (pt) * 2011-07-25 2017-01-31 Dritte Patentportfolio Beteili Ésteres de ácido carboxílico de amidoxima de dabigatrana como pró-drogas e utilização das mesmas como medicamento
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
WO2013024394A1 (fr) * 2011-08-12 2013-02-21 Alembic Pharmaceuticals Limited Nouveaux marqueurs de référence d'étéxilate de dabigatran
CN102993175B (zh) * 2011-09-08 2014-08-13 天津药物研究院 达比加群的酯衍生物及其制备方法和用途
CN102993174A (zh) * 2011-09-08 2013-03-27 天津药物研究院 作为前药的达比加群的酯衍生物
EP3309148A1 (fr) 2011-10-14 2018-04-18 Bristol-Myers Squibb Company Composés de tétrahydroisiquinoline substitués en tant qu'inhibiteurs du facteur xia
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
IN2014CN02806A (fr) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
AU2012357956A1 (en) 2011-12-22 2014-05-22 Boehringer Ingelheim International Gmbh Immediate release multi unit pellet system
WO2013111163A2 (fr) 2012-01-20 2013-08-01 Cadila Healthcare Limited Procédé de préparation de dabigatran étéxilate mésylate et polymorphes d'intermédiaires de celui-ci
WO2013110567A1 (fr) 2012-01-24 2013-08-01 Boehringer Ingelheim International Gmbh Nouvelle formulation de dabigatran à administration par voie orale
IN2014DN06734A (fr) 2012-02-21 2015-05-22 Esteve Labor Dr
EP2631234A1 (fr) 2012-02-23 2013-08-28 Esteve Química, S.A. Formes solides de mesylate d'étexilate de dabigatran et leurs procédés de préparation
WO2013144971A1 (fr) 2012-03-27 2013-10-03 Cadila Healthcare Limited Nouvelles formes solides de bisulfate et de mésylate d'étéxilate de dabigatran, et leurs procédés de préparation
WO2013150545A2 (fr) 2012-04-02 2013-10-10 Msn Laboratories Limited Procédés de préparation de dérivés de benzimidazole et de sels de ceux-ci
CN103387566B (zh) * 2012-05-09 2015-09-09 上海医药工业研究院 制备3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1h-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯的方法
CN103420980A (zh) * 2012-05-22 2013-12-04 北京美倍他药物研究有限公司 达比加群衍生物
WO2014001220A1 (fr) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Procédé de prévention d'un accident vasculaire cérébral
EP2872499A1 (fr) * 2012-07-16 2015-05-20 Interquim, S.A. Procédé de préparation d'intermédiaires pour la synthèse d'étexilate de dabigatran, et formes cristallines de ces intermédiaires
CN102766134B (zh) * 2012-07-19 2014-06-25 北京普禄德医药科技有限公司 达比加群的酯衍生物及其制备方法和用途
JP6193233B2 (ja) * 2012-07-31 2017-09-06 協和発酵キリン株式会社 縮環複素環化合物
JP6082462B2 (ja) 2012-08-03 2017-02-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１
EA028581B1 (ru) 2012-08-03 2017-12-29 Бристол-Маерс Сквибб Компани ДИГИДРОПИРИДОН Р1 В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa
WO2014041559A2 (fr) * 2012-08-27 2014-03-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Procédé de préparation d'étéxilate de dabigatran et ses intermédiaires
EP2722033A1 (fr) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques de Dabigatran sous forme de base libre
WO2014060561A1 (fr) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations pharmaceutiques orales contenant du dabigatran
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
US10077251B2 (en) 2012-10-29 2018-09-18 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of Dabigatran Etexilate and its intermediates
US9533971B2 (en) 2012-10-29 2017-01-03 Biophore India Pharmaceuticals Pvt. Ltd Process for the synthesis of dabigatran and its intermediates
CN102977077A (zh) * 2012-11-28 2013-03-20 浙江燎原药业有限公司 一种达比加群酯中间体的制备方法
EP2740471B1 (fr) 2012-12-07 2015-05-27 Hexal AG Composition pharmaceutique orale comprenant le dabigatran etexilate
CN103044404A (zh) * 2013-01-14 2013-04-17 中国药科大学 达比加群衍生物、其制法及抗血栓用途
CN105228996B (zh) 2013-03-25 2017-11-28 百时美施贵宝公司 作为因子XIa抑制剂的含取代唑类的四氢异喹啉
CN103224469A (zh) * 2013-05-16 2013-07-31 上海应用技术学院 一种以含氟基团修饰的苯环为中心的达比加群酯类似物及其合成方法
UY35592A (es) * 2013-06-03 2014-12-31 Bayer Pharma AG Benzoxazoles sustituidos
WO2014195230A1 (fr) 2013-06-03 2014-12-11 Bayer Pharma Aktiengesellschaft Benzoxazoles substitués
CN103288744A (zh) * 2013-06-04 2013-09-11 上海应用技术学院 一种含氟基团修饰的达比加群酯类似物及其合成方法
EP2853260A1 (fr) 2013-09-27 2015-04-01 ratiopharm GmbH Préparation pharmaceutique comprenant du dabigatran etexilate bismésylate
ES2687498T3 (es) 2014-01-31 2018-10-25 Bristol-Myers Squibb Company Macrociclos con grupos P2¿ heterocíclicos como inhibidores del factor XIa
NO2760821T3 (fr) 2014-01-31 2018-03-10
WO2015128875A2 (fr) 2014-02-26 2015-09-03 Megafine Pharma (P) Ltd. Procédé de préparation de dabigatran étéxilate mésylate et de ses intermédiaires
WO2015137680A1 (fr) * 2014-03-10 2015-09-17 동아에스티 주식회사 Composition pharmaceutique de traitement ou de prévention d'un accident vasculaire cérébral et de l'embolie systémique
WO2015145462A1 (fr) 2014-03-26 2015-10-01 Cadila Healthcare Limited Compositions pharmaceutiques de dabigatran
EP2929884A1 (fr) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et antagonistes du récepteur de h2
WO2015155281A1 (fr) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et d'inhibiteurs de la pompe à protons
CN104230888A (zh) * 2014-06-03 2014-12-24 长春工业大学 一种苯并咪唑化合物的制备方法
CN105218519A (zh) * 2014-06-04 2016-01-06 天津药物研究院 一种达比加群酯中间体的制备方法
CN104003977B (zh) * 2014-06-05 2016-04-13 雅本化学股份有限公司 N-(2-氯甲基-1-甲基-1h-苯并咪唑-5-酰基)-n-(吡啶-2-基) -3-氨基丙酸乙酯的制备方法
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN104045628B (zh) * 2014-06-13 2019-04-09 深圳翰宇药业股份有限公司 苯并咪唑衍生物的纯化方法
CN105315257A (zh) * 2014-06-24 2016-02-10 华仁药业股份有限公司 一种达比加群酯的合成及纯化方法
WO2016019848A1 (fr) * 2014-08-06 2016-02-11 四川海思科制药有限公司 Dérivé thioester du dabigatran, son procédé de préparation et son utilisation pharmaceutique
CN106536505A (zh) * 2014-08-06 2017-03-22 四川海思科制药有限公司 一种达比加群烷酯衍生物及其制备方法和在药学上的用途
NO2721243T3 (fr) 2014-10-01 2018-10-20
CA3001495C (fr) 2014-11-03 2021-07-20 Solipharma Llc Formulations de dabigatran etexilate ou sels de dabigatran etexilate et methodes de preparation associees
CN104592204B (zh) * 2014-12-26 2017-05-17 华润赛科药业有限责任公司 达比加群衍生物及其制备方法和用途
CN104650037A (zh) * 2014-12-30 2015-05-27 青岛黄海制药有限责任公司 一种达比加群酯的合成方法
TR201502223A2 (tr) 2015-02-25 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve dabigatranın farmasötik kombinasyonları.
CN104628733A (zh) * 2015-03-02 2015-05-20 中国药科大学 四氢苯并[4,5]咪唑并[1,2-a]吡嗪类凝血酶抑制剂
EP3310777B1 (fr) 2015-06-19 2019-10-09 Bristol-Myers Squibb Company Diamides macrocycliques en tant q'inhibiteurs du facteur xia
CN104987323B (zh) * 2015-07-10 2017-08-22 浙江美诺华药物化学有限公司 一种达比加群酯的制备方法
MA42480A (fr) 2015-07-20 2018-05-30 Sanovel Ilac Sanayi Ve Ticaret As Préparations pharmaceutiques de dabigatran sous forme de base libre
EP3868753B1 (fr) 2015-07-29 2022-12-21 Bristol-Myers Squibb Company Composés macrocycliques portant un groupe p2' non aromatique en tant qu'inhibiteurs de facteur xia
US10336730B2 (en) 2015-08-05 2019-07-02 Bristol-Myers Squibb Company Substituted glycine derived FXIA inhibitors
CN105294651A (zh) * 2015-09-23 2016-02-03 烟台东诚药业集团股份有限公司 一种用于合成制备达比加群酯脒化中间体的方法
CN106866626A (zh) * 2015-12-14 2017-06-20 天津药物研究院有限公司 一种达比加群酯中间体的制备方法
CN105481831B (zh) * 2015-12-16 2018-06-12 开封明仁药业有限公司 一种制备达比加群酯中间体的方法
WO2017111637A1 (fr) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Composition pharmaceutique comprenant du dabigatran ou un sel pharmaceutiquement acceptable de celui-ci
CN105566297A (zh) * 2015-12-31 2016-05-11 哈药集团技术中心 一种达比加群酯甲磺酸盐的制备方法
WO2017151746A1 (fr) 2016-03-02 2017-09-08 Bristol-Myers Squibb Company Macrocycles diamide présentant une activité inhibitrice du facteur xia
CN105669651B (zh) * 2016-03-07 2018-03-06 山东罗欣药业集团股份有限公司 一种甲磺酸达比加群酯的制备工艺
CN106397400A (zh) * 2016-04-14 2017-02-15 江苏康缘药业股份有限公司 一种达比加群酯的制备方法
TR201606697A2 (tr) 2016-05-20 2017-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin yeni̇ oral farmasöti̇k formülasyonlari
CN106349221A (zh) * 2016-08-29 2017-01-25 常州市阳光药业有限公司 高纯度达比加群酯的制备方法
TR201617984A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
EP3332771A1 (fr) 2016-12-07 2018-06-13 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions de comprimé multicouche de dabigatran
JP2018184375A (ja) 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
WO2019004980A2 (fr) 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques orales solides d'étéxilate de dabigatran
TR201706848A2 (tr) 2017-05-10 2018-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
CN109010249A (zh) * 2017-06-08 2018-12-18 上海美悦生物科技发展有限公司 注射用达比加群酯药物组合物及其制备方法和用途
KR20190036857A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 다비가트란 이텍실레이트를 포함하는 복합 캡슐제
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722186A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
TR201722630A2 (fr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN108864047A (zh) * 2018-07-02 2018-11-23 河南师范大学 一种非肽类凝血酶抑制剂达比加群酯的制备方法
EP3771465A1 (fr) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Composition pharmaceutique comprenant du dabigatran etexilate
CN111606885A (zh) * 2020-06-18 2020-09-01 安徽鼎旺医药有限公司 一种达比加群酯甲磺酸盐及其制备方法
CN113929661A (zh) * 2020-06-29 2022-01-14 石药集团恩必普药业有限公司 一种达比加群酯中间体及其制备方法
EP4070658A1 (fr) 2021-04-06 2022-10-12 BIORoxx GmbH Utilisation de composés anticoagulants comme rodenticides
CN116102536A (zh) * 2022-10-25 2023-05-12 浙江燎原药业有限公司 一种利用相转移催化剂制备达比加群酯的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675405A (en) * 1984-09-21 1987-06-23 American Home Products Corporation Quinoline compounds as antiallergic and antithrombotic agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
CA2134192A1 (fr) * 1993-11-12 1995-05-13 Michael L. Denney Antagonistes iib/iiia de la glycoproteine 5, 6-bicyclique

Also Published As

Publication number Publication date
JP3343359B2 (ja) 2002-11-11
AU742593B2 (en) 2002-01-10
SI0966454T1 (sl) 2003-10-31
SK285432B6 (sk) 2007-01-04
IL130812A0 (en) 2001-01-28
RS49686B (sr) 2007-12-31
ES2199426T4 (es) 2007-08-16
NO993945D0 (no) 1999-08-17
DE59808281D1 (de) 2003-06-12
HRP980082B1 (en) 2003-08-31
NL300349I1 (nl) 2008-08-01
CA2277949C (fr) 2006-10-03
BR9807843A (pt) 2001-06-19
NO313879B1 (no) 2002-12-16
CZ297768B6 (cs) 2007-03-28
BG64558B1 (bg) 2005-07-29
CA2277949A1 (fr) 1998-08-27
HU223754B1 (hu) 2005-01-28
NL300349I2 (nl) 2008-10-01
DE122008000020I1 (de) 2008-08-07
PT966454E (pt) 2003-09-30
YU38799A (sh) 2001-03-07
HRP980082A2 (en) 1998-10-31
KR20000071066A (ko) 2000-11-25
LTC0966454I2 (lt) 2021-08-10
KR100619458B1 (ko) 2006-09-08
TW588047B (en) 2004-05-21
NO2008012I2 (no) 2010-05-25
IL130812A (en) 2005-12-18
EG24144A (en) 2008-08-06
ES2199426T3 (es) 2004-02-16
NZ337323A (en) 2000-11-24
EP0966454B1 (fr) 2003-05-07
AU742593C (en) 2004-04-29
PL195551B1 (pl) 2007-10-31
AU6399198A (en) 1998-09-09
ATE239712T1 (de) 2003-05-15
SK112199A3 (en) 2000-05-16
EP0966454A1 (fr) 1999-12-29
CO4920237A1 (es) 2000-05-29
BG103655A (bg) 2000-02-29
NO993945L (no) 1999-10-15
PE121699A1 (es) 1999-12-08
CN1088702C (zh) 2002-08-07
AR010896A1 (es) 2000-07-12
BR9807843B1 (pt) 2010-06-29
CN1248251A (zh) 2000-03-22
LU91437I2 (fr) 2008-07-14
DK0966454T3 (da) 2003-09-01
HUP0001116A3 (en) 2001-07-30
EA199900746A1 (ru) 2000-08-28
CZ291599A3 (cs) 2000-06-14
NO2021005I1 (no) 2021-02-05
FR08C0025I2 (fr) 2009-11-20
HUP0001116A2 (hu) 2001-05-28
EE9900359A (et) 2000-02-15
EA003697B1 (ru) 2003-08-28
PL335154A1 (en) 2000-04-10
SA98190047B1 (ar) 2005-12-12
HK1025096A1 (en) 2000-11-03
JP2001509815A (ja) 2001-07-24
FR08C0025I1 (fr) 2008-07-18
TR199902017T2 (xx) 1999-10-21
EE04716B1 (et) 2006-10-16
WO1998037075A1 (fr) 1998-08-27
LTPA2008008I1 (lt) 2021-02-25
MY129408A (en) 2007-03-30
NO2008012I1 (no) 2008-08-25

Similar Documents

Publication Publication Date Title
BE2018C032I2 (fr)
LU91437I9 (fr)
IN189016B (fr)
ITMI971185A0 (fr)
IN184590B (fr)
IN185470B (fr)
ITMI971491A0 (fr)
ITTO970511A0 (fr)
IN183907B (fr)
ITMI971203A0 (fr)
IN184969B (fr)
ITTO970519A0 (fr)
ITRM970105V0 (fr)
ITMI971077A0 (fr)
ECSDI970457S (fr)
ECSMU970106U (fr)
ITMI970303V0 (fr)
ITGE970019V0 (fr)
ITMI971584A0 (fr)
ITBL970008V0 (fr)
IN190003B (fr)
IN189110B (fr)
BR9700653A (fr)
CN3055471S (fr)
CN3057976S (fr)